JP2011500073A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500073A5
JP2011500073A5 JP2010530432A JP2010530432A JP2011500073A5 JP 2011500073 A5 JP2011500073 A5 JP 2011500073A5 JP 2010530432 A JP2010530432 A JP 2010530432A JP 2010530432 A JP2010530432 A JP 2010530432A JP 2011500073 A5 JP2011500073 A5 JP 2011500073A5
Authority
JP
Japan
Prior art keywords
protein
seq
subunit
sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500073A (ja
JP5314033B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/064224 external-priority patent/WO2009053368A1/en
Publication of JP2011500073A publication Critical patent/JP2011500073A/ja
Publication of JP2011500073A5 publication Critical patent/JP2011500073A5/ja
Application granted granted Critical
Publication of JP5314033B2 publication Critical patent/JP5314033B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530432A 2007-10-22 2008-10-21 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ Expired - Fee Related JP5314033B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07118980 2007-10-22
EP07118980.7 2007-10-22
US714207P 2007-12-11 2007-12-11
US61/007,142 2007-12-11
PCT/EP2008/064224 WO2009053368A1 (en) 2007-10-22 2008-10-21 Single ifn-beta fused to a mutated igg fc fragment

Publications (3)

Publication Number Publication Date
JP2011500073A JP2011500073A (ja) 2011-01-06
JP2011500073A5 true JP2011500073A5 (enExample) 2011-12-08
JP5314033B2 JP5314033B2 (ja) 2013-10-16

Family

ID=39048918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530432A Expired - Fee Related JP5314033B2 (ja) 2007-10-22 2008-10-21 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ

Country Status (6)

Country Link
EP (1) EP2203180B1 (enExample)
JP (1) JP5314033B2 (enExample)
AU (1) AU2008314697B2 (enExample)
ES (1) ES2400107T3 (enExample)
IL (1) IL204948A (enExample)
WO (1) WO2009053368A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003202297C1 (en) 2002-01-25 2006-05-18 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
KR20100117120A (ko) 2008-02-20 2010-11-02 지투 인플레메이션 피티와이 엘티디 인간화된 항-Ｃ5ａＲ 항체
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
EP2536754A1 (en) * 2010-02-16 2012-12-26 Novo Nordisk A/S Factor viii fusion protein
EP2543730B1 (en) * 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
LT2647707T (lt) * 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
RU2616881C2 (ru) * 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
WO2013011062A2 (en) * 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP6849590B2 (ja) * 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
HRP20231578T1 (hr) 2015-11-25 2024-03-15 Visterra, Inc. Molekule protutijela na april i njihove uporabe
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
WO2017117464A1 (en) * 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3408397B1 (en) 2016-01-27 2020-07-15 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
WO2018185131A2 (en) * 2017-04-05 2018-10-11 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
JP2022513708A (ja) * 2018-12-05 2022-02-09 モルフォシス・アーゲー 多重特異性抗原結合分子
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7803910B2 (en) * 2005-01-24 2010-09-28 Merck Serono S.A. Soluble CD164 polypeptides
CN101184771A (zh) * 2005-05-26 2008-05-21 先灵公司 干扰素－IgG融合体

Similar Documents

Publication Publication Date Title
JP2011500073A5 (enExample)
Tang et al. Molecular medical microbiology
JP2012136541A5 (enExample)
JP2012126742A5 (enExample)
JP2011528896A5 (enExample)
JP2012095652A5 (enExample)
JP2010166916A5 (enExample)
JP2011528222A5 (enExample)
JP2016512425A5 (enExample)
JP2008536483A5 (enExample)
JP2012001560A5 (enExample)
JP2014530010A5 (enExample)
Villena et al. Lactiplantibacillus plantarum as a potential adjuvant and delivery system for the development of SARS-CoV-2 oral vaccines
JP2012524733A5 (enExample)
JP2013520176A5 (enExample)
JP2011528895A5 (enExample)
JP2010166921A5 (enExample)
JP2015523328A5 (enExample)
JP2013507907A5 (enExample)
JP2010522540A5 (enExample)
HRP20170193T1 (hr) Izolirani polipeptid iz proteina toksina a i toksina b iz c.difficile i njegove uporabe
JP2006149406A5 (enExample)
JP2010532656A5 (enExample)
JP2011528897A5 (enExample)
JP2013510169A5 (enExample)